MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Annals of Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,693 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,693 works in the cohort · of 4,299,418page 30 of 54

Labels cover 15 of 2,693 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,693 of 2,693 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Spin and bias: the tip of the iceberg
Francisco Vera-Badillo, Ian F. Tannock
2013· letter· en· Annals of Oncology· Mathematics
machine prediction:candidate · metaresearchconsensus · none
2
citations
affno abstractunlabeled
750P PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial
Brian M. Slomovitz, Nicoline Raaschou‐Jensen, Robert L. Coleman, Lucy Gilbert, Matthew A. Powell, David Cibula +14 more
2023· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
1902P Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)
Annie Lemelin, Kosuke Takemura, Devon J. Boyne, Matthew T. Warkentin, Darren R. Brenner, Wookwang Cheun +14 more
2023· article· en· Annals of Oncology· Economics, Econometrics and Finance
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
Reaching the pinnacle of stage III NSCLC treatment
Adrijana D’Silva, Howard Lau, Shannon Otsuka, R. Tudor, D. Gwyn Bebb
2016· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
A phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3Kα-selective inhibitor TAK-117 vs everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy
Toni K. Choueiri, Camillo Porta, C. Suárez Rodríguez, Robert Alter, Piotr Czaykowski, Ignacio Durán +8 more
2017· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
2
citations

How this was built: Screen · Findings · About